Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;27(9):1510-1511.
doi: 10.1038/s41591-021-01463-x.

A 'mix and match' approach to SARS-CoV-2 vaccination

Meagan E Deming  1 , Kirsten E Lyke  2
Affiliations
Comment

A 'mix and match' approach to SARS-CoV-2 vaccination

Meagan E Deming et al. Nat Med. 2021 Sep.

Abstract

Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses compared to the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. A Heterologous SARS-CoV-2 Vaccine Platform Induces Strong Immunity.
Heterologous dosing of an adenovirus-based vaccine (AstraZeneca’s ChAdOx1 nCoV-19) followed by an mRNA vaccine (either Pfizer–BioNTech’s BNT162b2 or Moderna’s mRNA-1273) results in robust humoral (yellow arrow) and cellular (red arrow) immunity compared to homologous adenovirus-based vaccination. The heterologous vaccine strategy improved induction of spike-specific CD8 T cells and neutralization of variants beyond that achieved by either of the homologous vaccine dosing strategies.
See this image and copyright information in PMC

Comment on

References

    1. Wise J Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 372, n699 (2021). - PubMed
    1. Barros-Martins J et al. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med (2021). - PMC - PubMed
    1. Schmidt T et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens. Nat. Med (2021).
    1. Borobia AM et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 6736, 1–10 (2021). - PMC - PubMed
    1. Zhu F et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 6736, (2020). - PMC - PubMed

Substances